These results build on a previous population-based study by the same group [ 164 ], which showed a trend of a decreased risk to progress to NVAMD in patients with higher plasma ω-3 LC-PUFAs.
1
—
—
These results build on a previous population-based study by the same group [ 164 ], which showed a trend of a decreased risk to progress to NVAMD in patients with higher plasma ω-3 LC-PUFAs.